FIGURE 5.
Model prediction. (A) Actual maximal efficacy (AEmax) of dapagliflozin on HbA1c; (B) after it reached the AEmax, the dapagliflozin therapeutic effect on HbA1c continuing the treatment for 0.5 years (26 weeks), at week 35; and (C) after it reached the AEmax, the dapagliflozin therapeutic effect on HbA1c continuing the treatment for 1 year (52 weeks) at week 61.